<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573638</url>
  </required_header>
  <id_info>
    <org_study_id>05-02-266</org_study_id>
    <secondary_id>Guarantor or CPI # 002533552</secondary_id>
    <nct_id>NCT00573638</nct_id>
  </id_info>
  <brief_title>Effects of Xal-Ease on Patient Compliance With Xalatan</brief_title>
  <acronym>Xal-Ease</acronym>
  <official_title>The Effects of the Xal-Ease Delivery Aid Device on Patient Compliance With Xalatan Eye Drops</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that the Xal-Ease with increase patient compliance with XALATAN
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2005</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is compliance with the medication XALATAN using and not using the Xal-Ease delivery aid for their glaucoma treatment.</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if any of the other factors mentioned in the survey affect compliance to their medical regimen</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To see whether or not the Xal-Ease device helps patients conserve medication. ie - aids in drops not distilled in the eye.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glaucoma</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xal-Ease device to be used with Xalatan eye drops</intervention_name>
    <description>This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  40 to 80 years old

          -  Diagnosis warranting treatment with Xalatan eye drops.

          -  ambulatory and well functioning

        Exclusion Criteria:

          -  non-ambulatory

          -  less than 40 or greater than 80 years old

          -  Not using Xalatan eye drops
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian D. Nilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian D. Nilson, MD</last_name>
    <phone>706-721-1150</phone>
    <email>cnilson@mail.mcg.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra M. Johnson, MD</last_name>
    <phone>706-721-1150</phone>
    <email>sajohnson@mail.mcg.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical College of Georgia Health Inc</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2007</study_first_posted>
  <last_update_submitted>August 7, 2008</last_update_submitted>
  <last_update_submitted_qc>August 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Michelle Christiano</name_title>
    <organization>Medical College of Georgia</organization>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>compliance</keyword>
  <keyword>eye drops</keyword>
  <keyword>deliver aid</keyword>
  <keyword>Patients could range anywhere from 40 to 80 years old</keyword>
  <keyword>Patients must have diagnosis requiring treatment with Xalatan.</keyword>
  <keyword>Patients will be male or female and from any racial/ethnic background.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 23, 2010</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>December 15, 2010</submitted>
    <returned>January 14, 2011</returned>
    <submitted>January 26, 2011</submitted>
    <returned>February 22, 2011</returned>
    <submitted>February 24, 2011</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>July 21, 2011</submitted>
    <returned>August 16, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

